SAN DIEGO — September 23, 2026
Travere Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, covering certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The allowed application, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” is expected to provide U.S. patent coverage for certain methods of using sparsentan in FSGS through October 2037 once the patent is issued. Travere said the application represents an additional intellectual property milestone for FILSPARI, which is indicated for reducing proteinuria in certain adults and pediatric patients with FSGS.
FILSPARI FSGS Patent Moves Toward Issuance
The allowed patent application is expected to issue as a U.S. patent following payment of the required issue fee and standard USPTO post-allowance processing. Following issuance, Travere expects to promptly submit the patent for listing in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The company said the expected patent term would extend certain U.S. method-of-use protection for sparsentan in FSGS into 2037, strengthening the intellectual property framework surrounding FILSPARI in the kidney disease indication.
Travere Expands Sparsentan Intellectual Property Protection
The FSGS Notice of Allowance follows a separate U.S. patent granted to Travere in August 2026 covering certain methods of using sparsentan in IgA nephropathy (IgAN). FILSPARI is indicated to slow kidney function decline in adults with primary IgAN who are at risk of disease progression and to reduce proteinuria in adult and pediatric patients aged eight years and older with FSGS without nephrotic syndrome. The company is therefore pursuing intellectual property protection around sparsentan across both of its approved kidney disease indications.
FILSPARI Carries Important Safety and Monitoring Requirements
FILSPARI is subject to a boxed warning for hepatotoxicity and embryo-fetal toxicity and is available only through the FILSPARI REMS program because of the hepatotoxicity risk. The prescribing information requires liver transaminase and bilirubin testing before treatment and every three months during treatment. FILSPARI is contraindicated during pregnancy and should not be coadministered with ARBs, other endothelin receptor antagonists or aliskiren. Other important risks include hypotension, acute kidney injury, hyperkalemia and fluid retention. The company’s latest patent milestone relates to intellectual property protection and does not change the product’s approved indications or existing safety requirements.
Source :Travere Therapeutics, press release



